Previous Article | Next Article 
Infection and Immunity, March 1999, p. 1432-1438, Vol. 67, No. 3
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Effect of Transforming Growth Factor
on
Experimental Salmonella typhimurium Infection in
Mice
Massimiliano
Galdiero,1
Antonella
Marcatili,2
Gabriella
Cipollaro
de l'ero,2
Immacolata
Nuzzo,2
Concetta
Bentivoglio,2
Marilena
Galdiero,2 and
Caterina Romano
Carratelli2,*
Dipartimento di Pathologia e Sanitá
Animale, Sezione Malattie Infettive, Facoltà di Veterinaria,
Università degli Studi di Napoli Federico
II,1 and Istituto di Microbiologia,
Facoltà di Medicina e Chirurgia, Seconda Università
degli Studi di Napoli,2 Naples, Italy
Received 2 April 1998/Returned for modification 21 May
1998/Accepted 15 December 1998
 |
ABSTRACT |
We have investigated the effect of the in vivo administration of
recombinant transforming growth factor
(rTGF-
) on the pathogenic
mechanisms involved in Salmonella typhimurium experimental infection in mice. The protective response elicited by macrophages was
induced by rTGF-
1 by 2 days after experimental
infection, as demonstrated by an increased NO production, while the
humoral protective effect began with cytokine mRNA expression 2 days
after the challenge and continued after 5 days with cytokine release and lymphocyte activation. We demonstrated that all mice who received rTGF-
1 survived 7 days after infection. The number of
bacteria recovered in the spleens and in the livers of
rTGF-
1-treated mice 2 and 5 days after infection was
significantly smaller than that found in the same organs after
phosphate-buffered saline (PBS) inoculation. Furthermore, 2 and 5 days
after infection, splenic macrophages from rTGF-
1-treated
mice showed a greater NO production than did those from PBS-treated
mice. The effect of rTGF-
1 on S. typhimurium
infection in mice was correlated with the expression of cell
costimulatory CD28 molecules. Five days after S. typhimurium infection, the percentage of
CD28+-expressing T cells in splenic lymphocytes from
rTGF-
1-treated mice increased with respect to that from
control mice. Gamma interferon (IFN-
) mRNA was present in a greater
amount in spleen cells from rTGF-
1-treated mice after 2 days, although the intensity of the band decreased 5 days after the
challenge. A similar pattern was obtained with the mRNAs for
interleukin-1
(IL-1
), IL-6, TGF-
, and inducible nitric oxide
synthase, which showed greater expression in cells obtained from
rTGF-
1-treated and S. typhimurium-infected mice 2 days after challenge. The treatment with rTGF-
1
induced an increase in IL-1
and IFN-
release in the supernatant
of splenocyte cultures 5 days after the experimental infection with
S. typhimurium. Moreover, we demonstrated that 5 days after
infection, the IFN-
titer was significantly greater in the sera of
rTGF-
-treated mice than in those of PBS-treated mice. Also, hsp60
showed greater expression 2 days after the challenge in splenocytes
from rTGF-
1-treated mice. The role played by
proinflammatory and immunoregulatory cytokines and by CD28 is discussed.
 |
INTRODUCTION |
Transforming growth factor
(TGF-
) is a 24-kDa protein produced by different cell types,
including B and T lymphocytes and activated macrophages (2, 23,
24), and is a multifunctional cytokine capable of a variety of
immunological effects. These include suppression of lymphocyte
responses to antigens and mitogens (24, 33), modulation of
the production and effects of monocyte proinflammatory cytokines
(11), and modulation of monocyte expression of surface
immunoregulatory molecules such as HLA-DR determinants (14)
and receptors for the Fc fragment of immunoglobulins (Fc
RIII and
CD16) (42). TGF-
inhibits both gamma interferon (IFN-
) (19) and interleukin-2 (IL-2) expression in T-cell responses (15), although there are no studies showing inhibition of
IL-2 expression in primary T cells (1, 40). TGF-
suppresses IL-2-dependent T-cell proliferation through inhibition of
IL-2-dependent phosphorylation of proteins that are important in T-cell
cycle progression (1). TGF-
plays an important role in
the progression of infections (as demonstrated by several studies) such
as those due to Mycobacterium avium (5),
Staphylococcus aureus (26), Leishmania
amazonensis (5), Leishmania brazilensis
(4, 5), Trypanosoma cruzi (34), and
Toxoplasma gondii (22). In recent studies,
TGF-
was shown to play a beneficial role in acquired resistance
against Listeria monocytogenes infections (28)
and during Candida albicans infections (35). In
experimental infection by Salmonella typhimurium in mice,
endogenous cytokines play important roles in host resistance correlated
to the development of Th1 and Th2 cell functions (21).
Since TGF-
is associated with both immunoregulation and control of
macrophage activities, in this study we have investigated the effect of
the in vivo administration of recombinant TGF-
1 (rTGF-
1) on some cellular and molecular mechanisms
involved in the inflammatory and immune response to S. typhimurium experimental infection in mice. Even though the
gastrointestinal tract is considered to be the natural route of
infection by Salmonella spp., we used intraperitoneal (i.p.)
challenge, since it is the most commonly used route in establishing an
experimental infection.
 |
MATERIALS AND METHODS |
Mice.
BALB/c mice weighing 20 to 25 g were obtained
from Nossan (Corezzana, Milan, Italy). These animals were maintained in
a controlled room (20 ± 2°C with automatic 12-h cycles of
lighting) and had free access to water. A group of 50 mice were each
treated with 0.5 µg of rTGF-
1 (A. F. Schnetzdeller, Tübingen, Germany) per ml by i.p. inoculation. A
control group of 50 mice were each inoculated with 0.01 M
phosphate-buffered saline (PBS) (pH 7.4).
Microorganism.
The microorganism used was S. typhimurium 74 NCTC grown in nutrient broth (Difco Laboratories,
Detroit, Mich.).
Experimental infection and CFU enumeration.
To establish the
experimental infection, mice were inoculated i.p. with PBS or
rTGF-
1 2 h before being infected with a sublethal dose of S. typhimurium (4 × 105
CFU/mouse). At 2 to 5 days after infection, a group of three mice were
killed by cervical dislocation, their spleens and livers were
aseptically removed and homogenized in 2 ml of PBS, and serial dilutions in sterile PBS were plated on nutrient agar. CFU were counted
after an overnight incubation.
Protection experiments.
Protection against experimental
infection was evaluated in two groups of 10 mice each. The control mice
were injected i.p. with PBS 2 h before being infected with 1 50%
lethal dose (LD50) of S. typhimurium 74 NCTC
(8 × 105 CFU/mouse) that had been prepared from
log-phase cultures, resuspended in sterile PBS, and administered i.p.
The other 10 mice were treated i.p. with rTGF-
1 (0.5 µg/mouse) 2 h before infection with being infected with 1 LD50 of S. typhimurium. The survival of
rTGF-
1-treated and untreated animals was observed during
the next 7 days.
Cell preparation and culture.
Spleens were aseptically
removed from the mice and minced, and the released cells were washed
three times in RPMI 1640 (Labtek Labs., Eurobio, Paris, France).
Erythrocytes were lysed with 0.17 M NH4Cl (9),
and the splenic cells were washed twice with RPMI 1640. Mononuclear
cells were isolated by centrifugation on an MSL (mileu de separations
des lymphocytes; Labtek Labs., Eurobio) at 600 × g for
30 min at room temperature. The isolated cells were suspended in RPMI
1640 supplemented with 10% fetal calf serum and antibiotics and
incubated for 1 h under 5% CO2 at 37°C in plastic
culture flasks. The adherent cells were cultured overnight in RPMI 1640 with 10% fetal calf serum. Cell viability was evaluated by the trypan
blue exclusion test. At least 96% of the cells thus obtained were
monocytes as determined with a FACS analyzer (Becton Dickinson,
Mountain View, Calif.) with monoclonal antibody CD14 (Boehringer,
Mannheim, Germany). Nonadherent cells (lymphocytes) were harvested,
washed, and resuspended at 3 × 106 cells/ml. Flow
cytometry analysis of stained cells with monoclonal antibody CD3
(Boehringer) demonstrated that more than 94% of the isolated cells
were lymphocytes.
Nitrite determination.
The nitrite concentration in 24-h
culture supernatants obtained from macrophages (107 cells)
isolated from mice which had received or not received rTGF-
1 2 h before experimental infection was
measured by a standard Griess reaction and compared to that in
supernatants obtained from macrophages of mice given PBS only
(control). Briefly, 0.1 ml of supernatant was mixed with 0.1 ml of
Griess reagent (0.5% sulfanilamide and 0.05%
N-1-naphthylenedimine hydrochloride in 2.5%
H3PO4) and incubated for 10 min at room
temperature, and the absorbance of the mixture at 570 nm was read with
a spectrophotometer. The data represent the means and standard
deviations of triplicate determinations and are expressed as micromoles
of NO2
/107 cells (10).
Cytokine release in vitro.
Splenic monocytes and lymphocytes
(3 × 106 cells/ml) from rTGF-
1-treated
mice were harvested at 2 and 5 days after infection with 4 × 105 cells of S. typhimurium and subjected to one
cycle of in vitro restimulation with Escherichia coli
O128:B12 lipopolysaccharide (Sigma Chemical Co., St. Louis, Mo.) (1 µg/ml). Control experiments were carried out with untreated mice.
After 24 h, the cell viability was checked and the culture
supernatants were collected and stored at
20°C until assayed for
IL-1
and tumor necrosis factor alpha (TNF-
) production. The
incubation time was prolonged to 48 h to determine IFN-
release
by splenic lymphocytes. All measurements were carried out with
monoclonal antibodies. Cytokine production was measured by
immunoenzymatic methods (Intertest Mouse IL-1
enzyme-linked
immunosorbent assay [ELISA] kit, Intertest Mouse TNF-
ELISA kit,
and Intertest Mouse IFN-
ELISA kit [Genzyme, Cambridge, Mass.]).
IFN-
and TNF-
release in vivo.
Mice were inoculated
i.p. with 0.5 µg of rTGF-
1 per ml or with PBS 2 h
before infection with S. typhimurium. IFN-
and TNF-
titers were determined in pooled sera 2 and 5 days after infection by
using immunoenzymatic methods (see above). Control experiments were
carried out with PBS-injected and infected mice.
RNA isolation and cDNA preparation.
Mice were inoculated
i.p. with 0.5 µg of rTGF-
1 or PBS 2 h before
infection with S. typhimurium. Cells were recovered 2 and 5 days after infection, and total RNA was extracted from spleen cells
(107) obtained from treated and untreated mice by the
method of Chomczynski and Sacchi (12). The RNA pellet was
resuspended in 75% ethanol, precipitated, vacuum dried, and dissolved
in 15 µl of RNase-free water. A 1-µg portion of oligo(dT) (Promega
Biotec, Madison, Wis.) was added to the suspension, and the mixture was
heated at 65°C for 5 min. After being cooled on ice, the mixture was
incubated for 2 h at 42°C with 14 µl of 20 mM dithiothreitol
(Sigma Chemical Co.); 1 mM (each) dATP, dGTP, dCTP, and dTTP; 35 U of
RNasin (Promega); and 525 U of Moloney murine leukemia virus reverse
transcriptase (Promega) in reverse transcription buffer.
PCR procedure.
Primer pair sequences were designed on the
basis of published gene sequences as indicated in Table
1. The primer sequences were
complementary to sequences in the exons or spanner exon-exon junctions
and thus were RNA specific. A 2-µl volume of cDNA prepared as
described above was amplified in the presence of 500 nM (final concentration) 5' and 3' primers; 200 µM (each) dATP, dGTP, dCTP, dTTP; and 1.25 U of Taq DNA polymerase (Promega) in a final
volume of 50 µl of Taq DNA polymerase 10× buffer
(Promega). The PCR was performed in a Perkin-Elmer thermal cycler for
30 cycles as follows: 1 min of denaturation at 94°C, 2 min of
annealing at 60°C, and 3 min of extension at 72°C. The reaction
product was visualized by electrophoresis with 25 µl of the reaction
mixture at 100 V in a 1.5% agarose gel containing ethidium bromide (1 µg/ml). The gels were then examined on a UV light box and
photographed. A 1-µg portion of BglI- and
HinfI-digested pBR328 DNA (Boehringer) was run in parallel
as a molecular size marker (providing bands at 2,176, 1,766, 1,230, 1,033, 653, 517, 453, 394, 298, 234, 220, and 154 bp).
Cytofluorometric analysis of CD28 expression.
Single- and
double-immunolabeling procedures were performed by standard techniques.
Briefly, splenic lymphocytes (106 cells) were suspended in
100 µl of RPMI 1640. Double staining was performed by pairing 1 µg
of fluorescein isothiocyanate-conjugated anti-CD3 with 1 µg of
phycoerythrin-conjugated anti-CD28 monoclonal antibody (Pharmingen, San
Diego, Calif.). After incubation at 0°C for 30 min, the cells were
washed with RPMI 1640 and analyzed by flow cytometry (FACS IV; Becton
Dickinson) (26).
Immunoblot analysis for hsp60.
Splenic lymphocytes were
washed three times in 0.01 M PBS (pH 7.2). Cell pellets were suspended
at 107 cells/ml in lysis buffer (50 mM Tris-HCl, Nonidet
P-40, 1% sodium dodecyl sulfate [SDS], 1 µM leupeptin, 100 µM
phenylmethylsulfonyl fluoride, 1 µM pepstatin A, 100 µM EDTA [pH
8.0]) for 30 min at 4°C. The insoluble debris were removed by
centrifugation at 18,600 × g for 10 min at 4°C. The
protein concentration was determined by the method of Lowry et al.
(27). Protein extracts were resuspended in sample buffer
(0.5 M Tris-HCl, 10% glycerol, 2% SDS, 2% 2-mercaptoethanol, 0.05%
bromophenol blue) and boiled for 3 min at 100°C. The proteins were
separated by SDS-polyacrylamide gel electrophoresis for 1 h at 20 mA. Proteins separated by SDS-polyacrylamide gel electrophoresis were
transferred to nitrocellulose filters (Bio-Rad Laboratories, Hercules,
Calif.) by electroblotting for 30 min to 1 h at 100 V with
cooling. Labeled antigen bands were detected with an immunoblot assay
kit (Bio-Rad Laboratories). The filters were blocked with 3% gelatin
in Tris-buffered saline (TBS) (20 mM Tris, 500 mM NaCl [pH 7.5]),
washed in TBS containing 0.05% Tween 20 (T-TBS), incubated with an
anti-hsp60 monoclonal antibody (1:1,000) (Biotechnologies Corp.,
Stress-Gen, Victoria, Canada) for 1 h at room temperature, and
then washed three times in T-TBS. The blots were incubated with a
1:3,000 dilution of peroxidase-labeled anti-mouse IgG for 1 h at
room temperature and washed in two changes of T-TBS and then once for 5 min in TBS. The reaction was stopped by washing the nitrocellulose
blots in water. Low-molecular-weight protein standards were used as a
reference (Pharmacia Biotech, Freiburg, Germany). In all cases,
nonspecific binding of antibodies to nitrocellulose was prevented by
blocking of the membranes with 1% bovine serum albumin in PBS for
2 h at room temperature.
The monoclonal antibody used was anti-hsp60, referenced in the
literature as clone LK-1, which is specific for an epitope located
between amino acids 383 and 447 of the human hsp 60-kDa sequence.
(28).
Statistics.
All experiments were carried out in triplicate;
the results are expressed, unless otherwise indicated, as the mean ± standard deviation. Comparison between tests was made by Student's
t test, with statistical significance considered to be
P < 0.01.
 |
RESULTS |
Effect of rTGF-
1 administration on survival of
infected mice.
We evaluated the effect of rTGF-
1 on
the survival of mice infected i.p. with 1 LD50 of S. typhimurium (8 × 105 cells). The results are
shown in Fig. 1. Mice that had received 0.5 µg of rTGF-
1 showed an increase in survival after
the experimental infection with S. typhimurium compared with
control mice, which were injected with PBS. All mice that had received
rTGF-
1 2 h before the S. typhimurium
infection were still alive after 7 days. After the same time, only 4 of
10 PBS-treated mice had survived. All the mice that were alive 7 days
after infection had survived after 30 days.

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 1.
Effect of rTGF- 1 administration on the
survival of mice infected with 1 LD50 of S. typhimurium (8 × 105 CFU/mouse). Ten mice were
injected i.p. with PBS 2 h before infection with S. typhimurium (×), and 10 mice were injected i.p. with 0.5 µg of
rTGF- 1 2 h before infection with S. typhimurium ( ). *, P < 0.01 with respect to
infected, nontreated mice.
|
|
Effect of rTGF-
1 administration on bacterial
invasion of the host.
The effect of rTGF-
1 on host
tissue bacterial invasion after a sublethal infection with S. typhimurium (4 × 105 cells) was evaluated. The
results are reported in Table 2. Mice were treated i.p. with 0.5 µg of rTGF-
1 per ml or with
PBS 2 h before infection. The numbers of bacterial cells in the
spleens and in the livers were determined 2 and 5 days after S. typhimurium infection. The number of bacteria recovered in the
spleens and the livers of rTGF-
1-treated mice 2 days
after infection was significantly smaller than that found in the same
organs of PBS-inoculated mice (P < 0.01). A similar
result was observed 5 days after infection.
NO production by macrophages in vitro.
To verify whether mouse
macrophages were able to kill S. typhimurium cells, we
studied NO release by macrophages isolated from mice that had received
or not received rTGF-
1 2 h before experimental
infection. Splenic adherent macrophages from mice treated with PBS or
with rTGF-
1 and then infected with a sublethal dose of
S. typhimurium (4 × 105 cells) were
compared for their relative ability to produce NO in vitro upon an
overnight incubation in the absence of activating stimuli. The results
are shown in Fig. 2. Two days after
infection, splenic macrophages from rTGF-
1-treated mice
showed NO production greater than that observed in macrophages from
PBS-treated mice. In particular, macrophages from
rTGF-
1-injected and infected mice were able to release
NO at 18 ± 4 µM whereas macrophages from PBS-treated and
infected mice produced NO at 4.8 ± 2 µM and macrophages from
PBS-only-injected mice released NO at 2 ± 1 µM. Five days after
infection, macrophages from rTGF-
1-treated mice also
produced more NO (20 ± 4 µM) than did those from PBS-injected mice. No further increase in NO production was observed when cultures from rTGF-
1-treated and infected mice were treated with
IFN-
as the activating stimulus (data not shown).

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 2.
Nitric oxide production by splenic macrophages from mice
treated with PBS or 0.5 µg of rTGF- 1 2 h before
sublethal infection with S. typhimurium (4 × 105 CFU/mouse). Symbols: , PBS-only-injected mice; ,
TGF- 1-only-injected mice; , PBS-injected, infected
mice; , rTGF- 1-injected (0.5 µg), infected mice.
Each result represents the mean of three determinations, and the bars
indicate standard deviations. *, P < 0.01 with
respect to PBS-injected, infected mice.
|
|
Effect of rTGF-
1 on CD28 expression in mice infected
with S. typhimurium.
Costimulatory molecules are thought to
be critical in eliciting cellular proliferation and cytokine production
upon immunologic stimulation. We therefore attempted to determine if
the effect of rTGF-
1 on sublethal S. typhimurium infection in mice was correlated with the expression
of the T-cell costimulatory CD28 molecules. Single and double
immunolabeling with anti-CD28 and anti-CD3 monoclonal antibodies
revealed that the percentages of CD28-expressing T cells in splenic
lymphocytes which were treated with rTGF-
1 and infected
and those in control mice were similar 2 days after experimental infection (35% ± 6% and 33% ± 6%, respectively). Five days after S. typhimurium infection, the percentage of
CD28+-expressing T cells in splenic lymphocytes from
rTGF-
1-treated mice increased with respect to the
percentage for control mice (P < 0.01). Furthermore,
the percentage of CD3-expressing cells in splenic lymphocytes from
rTGF-
1-injected mice increased significantly compared to
that for PBS-treated mice (P < 0.01). The results are
shown in Table 3.
Cytokine release in vitro from cells of infected and uninfected
rTGF-
1-treated mice.
To explore the involvement of
TGF-
1 in the immune response to S. typhimurium, we analyzed IL-1
, TNF-
, and IFN-
production in vitro by using splenic monocytes or lymphocytes obtained from rTGF-
1-treated and untreated mice infected with S. typhimurium. Cells were harvested 2 and 5 days after treatment and
subjected to one cycle of in vitro restimulation with
lipopolysaccharide (1 µg/ml) for 24 and 48 h. As shown in Fig.
3, the amount of IL-1
in the
supernatant of splenic monocytes from rTGF-
1-treated
mice 2 days after infection did not increase significantly with respect to that found in monocytes from PBS-injected mice. In contrast, 5 days
after infection, the amount of IL-1
released by splenic lymphocytes
from rTGF-
1-treated animals (1,400 ± 37 pg/ml)
increased significantly compared to the amount released by lymphocytes
from PBS-injected mice (800 ± 28 pg/ml) (P < 0.01). As shown in Fig. 3, IFN-
release followed a similar
pattern, with a greater amount being found in the supernatant of
rTGF-
1-treated mice 5 days after infection (1,800 ± 42 pg/ml). TNF-
release was not significant after 2 and 5 days
after infection in rTGF-
1-treated mice or in
PBS-injected mice (data not shown).

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 3.
Effect of rTGF- 1 administration on
IL-1 ( , , , and ) and IFN- ( , , , and )
release in the supernatants of monocytes from S. typhimurium-infected mice (4 × 105 CFU/mouse).
Results for PBS-only-treated mice ( and ),
rTGF- 1-only-treated mice ( and ), PBS-treated and
infected mice ( and ), and rTGF- 1-treated and
infected mice ( and ) are shown. Each result represents the mean
of three determinations, and the bars indicate standard deviations.
*, P < 0.01 with respect to PBS-injected, infected
mice.
|
|
Effect of TGF-
1 on endogenous IFN-
and TNF-
induced by a sublethal infection with S. typhimurium.
At 2 and 5 days after mice were infected with 4 × 105 CFU
of S. typhimurium, the levels of IFN-
and TNF-
in the
bloodstream were monitored. In a previous study by Nakane et al.
(28), the titers of endogenous IFN-
and TNF-
in sera
peaked 2 to 3 days after the sublethal infection. In our study, we
demonstrated that 2 days after infection the amount of IFN-
in the
serum of rTGF-
1-treated mice (2,250 ± 45 pg/ml)
and in the serum of PBS-injected mice (2,220 ± 45 pg/ml) was not
significantly different even if it was increased with respect to that
in control mice. As shown in Fig. 4, 5
days after infection the IFN-
titer was significantly greater in the
serum of rTGF-
1-treated mice (3,261 ± 57 pg/ml) than in the serum of PBS-treated mice (2,591 ± 51 pg/ml). No
endogenous TNF-
was observed in the bloodstream of
rTGF-
1- or PBS-treated mice (data not shown).

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 4.
Effect of rTGF- 1 administration on the
amount of IFN- in the serum of S. typhimurium-infected
mice (4 × 105 CFU/mouse). Symbols: ,
PBS-only-treated mice; , rTGF- 1-only-treated mice;
, PBS treated, infected mice; , rTGF- 1-treated,
infected mice. Each result represents the mean of three determinations,
and the bars indicate standard deviations. *, P < 0.01 with respect to PBS injected, infected mice.
|
|
Detection of cytokine and iNOS mRNA.
Cytokine mRNA analysis of
spleen cells from rTGF-
1-treated and untreated mice
after S. typhimurium infection was performed by reverse
transcriptase PCR (RT-PCR) and focused on tissue from mice at 2 and 5 days after treatment. At our limits of detection, mRNAs for IL-1
,
IL-6, IFN-
, IL-4, TGF-
, and inducible nitric oxide synthase
(iNOS) were not expressed in spleen cells from untreated mice and mRNAs
for IL-10 and TNF-
were barely expressed. The pattern of cytokine
mRNA expression in splenocytes from rTGF-
1-treated and
untreated mice, 2 and 5 days after a sublethal infection with S. typhimurium, is shown in Fig. 5.

View larger version (50K):
[in this window]
[in a new window]
|
FIG. 5.
RT-PCR analysis of cytokine mRNA expression in spleens
of mice 2 and 5 days after S. typhimurium infection. Mice
were inoculated i.p. with 0.5 µg of rTGF- 1 or PBS
2 h before infection with S. typhimurium, and cells
were recovered 2 and 5 days after infection. Total RNA was isolated
from 107 splenocytes obtained from treated and untreated
mice and RT-PCR amplified with specific primer pairs. The reaction
products were run on 1.5% agarose gels in the presence of appropriate
molecular size markers (providing bands at 2,176, 1,766, 1,230, 1,033, 653, 517, 453, 394, 298, 234, 220, and 154 bp) (arrow); -actin was
the positive transcription control.
|
|
By RT-PCR analysis, IFN-
mRNA was detected in spleen cells from
PBS-injected mice after 2 days, although the band was weak and had
disappeared entirely by 5 days after the challenge. In rTGF-
1-treated mice, IFN-
mRNA was present in a
greater amount than in untreated mice after 2 days, although the
intensity of the band had decreased by 5 days after the challenge. A
similar pattern was obtained with the mRNAs for IL-1
, IL-6, TGF-
,
and iNOS, which showed their greater expression in cells obtained from
rTGF-
1-treated and S. typhimurium-infected
mice 2 days after challenge. IL-4 mRNA was absent both 2 and 5 days
after the different treatments.
hsp appearance in splenocytes from rTGF-
1-treated
mice after S. typhimurium infection.
The presence of
hsp60 was checked in murine splenocytes from
rTGF-
1-treated animals by using a monoclonal antibody to
hsp60 (clone LK-1). The number of cells that we used (107)
was not enough to show the presence of constitutive hsp in splenocytes from untreated control mice by immunoblotting. Two days after infection, rTGF-
1-treated mice showed greater expression
of hsp60 than did PBS-injected mice. In contrast, 5 days after
infection, higher expression of hsp60 was found in splenocytes from
PBS-injected mice but the expression was lower in splenocytes from
rTGF-
1-treated mice. Results of a representative
experiment are shown in Fig. 6.

View larger version (69K):
[in this window]
[in a new window]
|
FIG. 6.
Time course of hsp expression (estimated by
immunoblotting) in splenic lymphocytes from
rTGF- 1-treated mice. Lanes: 1, control mice; 2, rTGF- 1-only-treated mice 2 days after injection; 3, PBS-treated mice 2 days after infection; 4, rTGF- 1-treated mice 2 days after infection; 5, rTGF- 1-only-treated mice 5 days after injection; 6, PBS-treated mice 5 days after infection; 7, rTGF- 1-treated mice 5 days after infection.
|
|
 |
DISCUSSION |
The role of TGF-
in immune responses might involve complicated
mechanisms; it is considered to play a key role in the regulation of
infection with certain intracellular microorganisms. It modulates the
production of cytokines and the cell response to cytokine stimulation.
TGF-
plays an important role in the progression of
Mycobacterium avium infection (41); its
production in vivo is considered to be a virulence mechanism in
protozoan infections. Early treatment in vivo with rTGF-
was
demonstrated to induce a protective effect against experimental
infection with L. monocytogenes in mice (28).
Furthermore, in mice infected with virulent C. albicans, the
administration of rTGF-
delays progression of the disease
(35).
The resistance to infections is related to the development of a Th1-Th2
response. The preferential development of CD4+ or
CD8+ Th1 or Th2 cells is under the control of several
mechanisms. The early presence of Th1 or Th2 cytokines influences the
outcome of the type of the cells that will develop. IL-4 plays an
important role in stimulating Th2 response, whereas IFN-
and TGF-
favor the development of the Th1 response (20, 36). The
treatment with TGF-
could be protective either by promoting the
generation of Th1 cells or by regulating the synthesis and release of
proinflammatory cytokines.
Our studies demonstrate that after 2 days, treatment with
rTGF-
1 before experimental infection with S. typhimurium induces an increase in the mRNA expression of
cytokines that promote the development of a Th1 response. This effect
tends to decline 5 days after the infection. The cytokine pattern is
related to the activation of both specific and nonspecific mechanisms
of host defense; in fact, we observed that rTGF-
1
administration affected the activation of macrophages (as demonstrated
by NO production), the expression of molecules involved in the immune
response (CD28), and the induction of cellular stress (as shown by
hsp60 expression). Treatment with rTGF-
1 2 h before
the experimental infection led to the survival of all infected mice, in
comparison with the mortality rate of 4 to 5 of 10 observed in
PBS-injected mice which received 8 × 105 CFU of
S. typhimurium. This survival rate is related to a
remarkably smaller number of bacteria in the spleens and livers of
rTGF-
1-treated mice compared to control mice. The
smaller number of CFU in these organs is related to the higher NO
production as demonstrated in vitro by macrophages obtained from
rTGF-
1-treated mice. Macrophage NO release is suppressed
by TGF-
(15), and inhibition of NO production in vivo is
associated with impaired Th1-cell development (18) and
effector function (17, 37). Under our experimental conditions, S. typhimurium-infected mice show enhanced NO
production, which further increases in rTGF-
1-treated
mice. While in vitro the production of TGF-
is associated with an
inhibition of NO production (15), under our experimental
conditions the in vivo treatment does not have the same effect,
probably because of the presence of the other regulatory cytokines. The
amounts of IL-1
and IFN-
increase remarkably in vivo during
rTGF-
1 administration, as shown by their mRNA expression
and release by cell culture. It is of great interest that IL-1 and
IFN-
are cytokines that contribute to an enhanced NO response
(17). Our findings demonstrate that 2 days after infection,
administration of rTGF-
1 induces greater expression of
IFN-
and TNF-
mRNA, which directly or indirectly also promote the
activation of macrophages.
Because the costimulatory molecules can decisively influence the
evolution of a protective response and because intracellular pathogens
downregulate the expression of specific costimulating molecules, we
became interested in analyzing the expression of CD28 in
CD3+ cells in infected mice and in
rTGF-
1-treated and infected mice. The administration of
rTGF-
1 induces an upregulation of CD28 expression 5 days
after infection. Under our experimental conditions, the upregulation of
the costimulatory molecule (CD28) is preceded at 2 days after S. typhimurium infection by a remarkable upregulation of IFN-
mRNA
expression. The T-cell costimulatory molecule CD28 plays a critical
role in T-cell activation and cytokine production. CD28 is present on
resting T cells and is therefore likely to predominate in initial
costimulatory activity. The findings in this report provide insight
into the mechanism by which TGF-
regulates immune responses through
the network of cytokines and costimulatory molecules.
Recombinant TGF-
1 treatment greatly influences the
proinflammatory and immunoregulatory cytokine pattern 2 days after
infection, while only IFN-
release is still enhanced at later times.
IFN-
was detected after 2 and 5 days in the bloodstream in a larger amount in rTGF-
1-treated mice infected with S. typhimurium than in untreated, infected mice. TNF-
was never
found in the bloodstream at 2 and 5 days after infection. Greater
IFN-
, TNF-
, and IL-10 mRNA expression was always seen in the
spleens of TGF-
1-treated mice after S. typhimurium infection than in those of PBS-injected mice. IL-6
mRNA expression was barely evident in PBS-treated, infected mice but
showed a good rate of induction in rTGF-
1-injected mice.
IL-6 has a wide variety of activities; IL-6 pretreatment enhances
resistance against infection (6, 38), although this has not
been found consistently (8). IL-4 mRNA was never detected under the same experimental conditions. TGF-
mRNA showed good expression in the spleens of infected mice compared to control animals.
The administration of rTGF-
1 further increases this upregulation during the first 2 days of infection. Endogenous TGF-
expression is also upregulated by TGF-
priming, which is consistent
with TGF-
autoinduction in other cell types (39). The
functional pattern of the cytokines expressed and released in the
spleens of infected animals either treated or not treated with
rTGF-
1 is related to a Th1 response. Our findings
demonstrate a cytokine pattern related to activation of
CD8+ effector production as revealed by splenic mRNA
analysis. The influence of certain cytokines on the development of
naive CD4+ T cells to express Th1 and Th2 cytokines is well
recognized for the dominant effects of IL-12 and IL-4, respectively
(31). More recently, Th1- and Th2-like cytokine patterns
have also been demonstrated by CD8+ T cells upon antigen
priming in the presence of IL-12 or IL-4 (13, 32, 43) and
upon TGF-
priming. CD8+ cells primed by TGF-
are
typified by a distinct cytokine profile of IL-10 and TGF-
production
(30). TGF-
growth response occurs predominantly among
CD8+ T cells of naive CD44low
CD45RBhigh phenotype, which usually accounts for more than
85% of splenic CD8+ T cells of young, conventionally
maintained BALB/c or C57BL/6 mice (25).
In our study TGF-
1 is associated with a faster
appearance (2 days) of hsp60 in splenic cells and with a faster
disappearance (5 days) in untreated and rTGF-treated mice,
respectively. The lower level of hsp60 5 days after infection in
rTGF-
1 treated mice (compared to untreated mice) may
depend on a decrease of the bacterial load in the spleen or on a direct
effect of TGF-
on the recovery of cellular activities. Rich et al.
(29) suggest that there is a TGF-
-dependent protection of
CD8+ T cells from apoptosis.
In conclusion, the greater resistance to infection with S. typhimurium in rTGF-
1-treated mice is associated
under our experimental conditions with different mechanisms, both
nonspecific (NO production and hsp) and specific (costimulatory
molecules activation and release of cytokines), in the protective
response. The widespread distribution of TGF-
(and its receptors)
suggests that it plays an important role in these mechanisms, whose
final result depends on several variables (TGF-
concentration and
time of production, cell type, and degree of differentiation).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Istituto di
Microbiologia, Facoltà di Medicina e Chirurgia, Seconda
Università degli Studi di Napoli, Larghetto S. Aniello a
Caponapoli 2, 80138 Naples, Italy. Phone: 0039-81-5665663. Fax:
0039-81-5665663.
Editor:
R. N. Moore
 |
REFERENCES |
| 1.
|
Ahuja, S. S.,
F. Paliogianni,
Y. Hidehiro,
J. E. Balow, and D. T. Boumpas.
1993.
Effect of transforming growth factor- on early and late activation events in human T cells.
J. Immunol.
150:3109-3118[Abstract].
|
| 2.
|
Assoian, R. K.,
B. E. Fleurdelys,
H. C. Stevenson,
P. J. Miller,
D. K. Madres,
E. W. Raines,
R. Ross, and M. B. Sporn.
1987.
Expression and secretion of type transforming growth factor by activated human macrophages.
Proc. Natl. Acad. Sci. USA
84:6020-6024[Abstract/Free Full Text].
|
| 3.
|
Barnes, D. F.,
S. D. Mistry,
C. L. Cooper,
C. Pirmez,
T. H. Rea, and R. L. Modlin.
1989.
Compartmentalization of a CD4+ T lymphocyte subpopulation in tuberculous pleuritis.
J. Immunol.
142:1114-1119[Abstract].
|
| 4.
|
Barral, A.,
M. Barral-Netto,
E. C. Young,
E. Brownell,
D. R. Twardzik, and S. G. Reed.
1993.
Transforming factor- as a virulence mechanism for Leishmania braziliensis.
Proc. Natl. Acad. Sci. USA
90:3442-3446[Abstract/Free Full Text].
|
| 5.
|
Barral-Netto, M.,
A. Barral,
C. E. Brownell,
Y. A. W. Skeiky,
L. R. Ellingsworth,
D. R. Twardzik, and S. G. Reed.
1992.
Transforming growth factor- in leishmanial infection: a parasite escape mechanism.
Science
257:545-548[Abstract/Free Full Text].
|
| 6.
|
Barton, B. E., and J. V. Jackson.
1993.
Protective role of interleukin-6 in the lipopolysaccharide-galactosamine septic shock model.
Infect. Immun.
61:1496-1499[Abstract/Free Full Text].
|
| 7.
|
Boog, E. R.,
E. R. de Graeff-Meeder,
M. A. Lucassen,
R. van der Zee,
M. M. Voorhorst-Ogink,
P. J. van Kooten,
H. J. Geuze, and W. Van Eden.
1992.
Two monoclonal antibodies generated against human HSP60 show reactivity with synovial membranes of patients with juvenile chronic arthritis.
J. Exp. Med.
175:1805-1810[Abstract/Free Full Text].
|
| 8.
|
Bucklin, S. E.,
R. Silverstein, and D. C. Morrison.
1993.
An interleukin-6-induced acute-phase response does not confer protection against lipopolysaccharide lethality.
Infect. Immun.
61:3184-3189[Abstract/Free Full Text].
|
| 9.
|
Buttke, T. M.
1984.
Inhibition of lymphocyte proliferation by free fatty acids.
Immunology
53:5-42.
|
| 10.
|
Cenci, E.,
L. Romani,
A. Mencacci,
R. Spaccapelo,
E. Schiaffella,
P. Puccetti, and F. Bistoni.
1993.
Interleukin-4 and interleukin-10 inhibit nitric oxide-dependent macrophage killing of Candida albicans.
Eur. J. Immunol.
23:1034-1038[Medline].
|
| 11.
|
Chantry, D.,
M. Turner,
E. Abney, and M. Feldman.
1989.
Modulation of cytokine production by TGF- .
J. Immunol.
142:4295-4300[Abstract].
|
| 12.
|
Chomczynski, P., and N. Sacchi.
1987.
Single step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction.
Anal. Biochem.
162:156-159[Medline].
|
| 13.
|
Croft, M.,
L. Carter,
S. Swain, and R. W. Dutton.
1994.
Generation of polarized antigen-specific CD8 effector populations: reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles.
J. Exp. Med.
180:1715-1728[Abstract/Free Full Text].
|
| 14.
|
Czariecki, C. W.,
H. H. Chiu,
G. H. W. Wong,
S. M. McCabe, and M. A. Palladino.
1988.
Transforming growth factor- 1 modulates the expression of class II histocompatibility antigens on human cells.
J. Immunol.
140:4217-4223[Abstract].
|
| 15.
|
D'Angeac, A. D.,
J. Dornand,
J. A. Emonds,
A. X. Garcia-Sanz, and F. Erard.
1991.
Transforming growth factor- 1 down-regulates interleukin-2 production and up-regulates interleukin-2 receptor expression in a thymoma cell line.
J. Cell. Physiol.
147:460-469[Medline].
|
| 16.
|
Denis, M., and E. Ghadirian.
1991.
Transforming growth factor- 1 (TGF- 1) plays a detrimental role in the progression of experimental Mycobacterium avium infection: in vivo and in vitro evidence.
Microb. Pathog.
11:367-372[Medline].
|
| 17.
|
Ding, A. H.,
C. F. Nathan, and D. J. Stuehr.
1988.
Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production.
J. Immunol.
141:2407-2412[Abstract].
|
| 18.
|
Ellner, J. J.
1978.
Suppressor cells in tuberculosis.
J. Immunol.
121:2573-2579[Abstract/Free Full Text].
|
| 19.
|
Espevik, T.,
I. S. Figari,
M. R. Shalaby,
G. A. Lackides,
G. D. Lewis,
M. Shepard, and M. A. Palladino.
1987.
Inhibition of cytokine production by cyclosporin A and transforming growth factor .
J. Exp. Med.
166:571-576[Abstract/Free Full Text].
|
| 20.
|
Gajewski, T. F., and F. W. Fitch.
1988.
Anti-proliferative effect of IFN- in immune regulation. I. IFN- inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones.
J. Immunol.
140:4245-4252[Abstract].
|
| 21.
|
Galdiero, F.,
G. Cipollaro de L'Ero,
N. Benedetto,
M. Galdiero, and M. A. Tufano.
1993.
Release of cytokines induced by Salmonella typhimurium porins.
Infect. Immun.
61:155-161[Abstract/Free Full Text].
|
| 22.
|
Hunter, C. A.,
L. Bermudez,
H. Beernink,
W. Waegell, and J. S. Remington.
1995.
Transforming growth factor- inhibits interleukin-12-induced production of interferon- by natural killer cells: a role for transforming growth factor- in the regulation of T cell-independent resistance to Toxoplasma gondii.
Eur. J. Immunol.
25:994-1000[Medline].
|
| 23.
|
Kehrl, J. H.,
A. B. Roberts,
L. M. Wakefield,
S. Jakowlew,
M. B. Sporn, and A. S. Fauci.
1986.
Transforming growth factor- is an important immunomodulatory protein for human B lymphocytes.
J. Immunol.
137:3855-3860[Abstract].
|
| 24.
|
Kehrl, J. H.,
L. M. Wakefield,
A. B. Roberts,
S. Jakowlew,
M. Alverez-Mon,
R. Derynck,
M. B. Sporn, and A. S. Fauci.
1986.
Production of transforming growth factor- by human T lymphocytes and its potential role in the regulation of T cell growth.
J. Exp. Med.
163:1037-1050[Abstract/Free Full Text].
|
| 25.
|
Lee, H. M., and S. Rich.
1991.
Costimulation of T cell proliferation by transforming growth factor- 1.
J. Immunol.
147:1127-1133[Abstract].
|
| 26.
|
Lowrance, J. H.,
F. X. O'Sullivan,
T. E. Caver,
W. Waegell, and H. D. Gresham.
1994.
Spontaneous elaboration of transforming growth factor suppresses host defence against bacterial infection in autoimmune MRL/lpr mice.
J. Exp. Med.
180:1693-1703[Abstract/Free Full Text].
|
| 27.
|
Lowry, O. H.,
N. J. Rosebrough,
A. L. Farr, and R. J. Randall.
1951.
Protein measurement with the Folin phenol reagent.
J. Biol. Chem.
193:265-275[Free Full Text].
|
| 28.
|
Nakane, A.,
M. Asano,
S. Sasaki,
S. Nishikawa,
T. Miura,
M. Kohanawa, and T. Minagawa.
1996.
Transforming growth factor is protective in host resistance against Listeria monocytogenes infection in mice.
Infect. Immun.
64:3901-3904[Abstract].
|
| 29.
|
Rich, S.,
M. Seelig,
H. M. Lee, and J. Lin.
1995.
Transforming growth factor 1 costimulated growth and regulatory function of staphylococcal enterotoxin B-responsive CD8+ T cells.
J. Immunol.
155:609-618[Abstract].
|
| 30.
|
Salgame, P.,
J. S. Abrams,
C. Clayberger,
H. Goldstein,
J. Convit,
R. L. Modlin, and B. R. Bloom.
1991.
Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones.
Science
254:279-282[Abstract/Free Full Text].
|
| 31.
|
Seder, R. A., and W. E. Paul.
1994.
Acquisition of lymphokine producing phenotype by CD4+ T cells.
Annu. Rev. Immunol.
12:635-673[Medline].
|
| 32.
|
Seder, R. A.,
J. L. Boulay,
F. Finkelman,
S. Barbier,
S. Z. Ben-Sasson,
G. Le Gros, and W. E. Paul.
1992.
CD8+ T cells can be primed in vitro to produce IL-4.
J. Immunol.
148:1652-1656[Abstract].
|
| 33.
|
Shalaby, M. R., and A. J. Amman.
1988.
Suppression of immune cell function in vitro by recombinant human transforming growth factor .
Cell. Immunol.
112:343-350[Medline].
|
| 34.
|
Silva, J. S.,
D. R. Twardizik, and S. G. Reed.
1991.
Regulation of Trypanosoma cruzi infections in vitro and in vivo by transforming growth factor- (TGF- ).
J. Exp. Med.
172:1774-1777.
|
| 35.
|
Spaccapelo, R.,
L. Romani,
L. Tonnetti,
E. Cenci,
A. Mencacci,
G. Del Sero,
R. Tognellini,
S. G. Reed,
P. Puccetti, and F. Bistoni.
1995.
TGF- 1 is important in determining the in vivo patterns of susceptibility or resistance in mice infected with Candida albicans.
J. Immunol.
155:1349-1360[Abstract].
|
| 36.
|
Swain, S. L.,
L. M. Bradley,
M. Croft,
S. Tonkonogy,
G. Atkins,
A. D. Weinberg,
D. D. Duncan,
S. M. Hedrick,
R. W. Dutton, and G. Huston.
1991.
Helper-cell subset phenotype, function and the role of lymphokines in regulating their development.
Immunol. Rev.
123:115-144[Medline].
|
| 37.
|
Toossi, Z.,
J. P. Lapurga,
R. J. Ondash,
J. R. Sedor, and J. J. Ellner.
1990.
Expression of functional interleukin-2 receptors by peripheral blood monocytes from patients with active pulmonary tuberculosis.
J. Clin. Invest.
85:1777-1784.
|
| 38.
|
Van der Meer, J. W. M.,
M. Helle, and A. Aarden.
1989.
Comparison of the effects of recombinant interleukin-6 and recombinant interleukin-1 on non- specific resistance to infection.
Eur. J. Immunol.
19:413-416[Medline].
|
| 39.
|
Van Obberghen-Schilling, E.,
N. S. Roche,
K. C. Flanders,
M. Sporn, and A. Roberts.
1988.
Transforming growth factor 1 positively regulates its own expression in normal and transformed cells.
J. Biol. Chem.
263:7741-7746[Abstract/Free Full Text].
|
| 40.
|
Wahl, S. M.,
D. A. Hunt,
L. M. Wakefield,
N. McCartney-Francis,
L. M. Wahl,
A. B. Roberts, and M. B. Sporn.
1987.
Transforming growth factor type induces monocyte chemotaxis and growth factor production.
Proc. Natl. Acad. Sci. USA
84:5788-5792[Abstract/Free Full Text].
|
| 41.
|
Wahl, S. M.,
D. A. Hunt,
H. L. Wong,
S. Dougherty,
N. McCartney Francis,
L. M. Wahl,
L. Ellingsworth,
J. A. Schmidt,
G. Hall,
A. B. Roberts, and M. B. Sporn.
1988.
Transforming growth factor- is a potent immunosuppressive agent which inhibits interleukin-1 dependent lymphocyte proliferation.
J. Immunol.
140:3026-3032[Abstract].
|
| 42.
|
Welch, G. R.,
M. L. Wong, and S. M. Wahl.
1990.
Selective induction of Fc RIII on human monocytes by TGF- .
J. Immunol.
144:3444-3448[Abstract].
|
| 43.
|
Wild, E. M. T.,
J. A. Garcia-Sanz, and G. Le Gros.
1993.
Switch of CD8 T cells to noncytolytic CD8 CD4 cells that make Th2 cytokines and help B cells.
Science
260:1802-1805[Abstract/Free Full Text].
|
Infection and Immunity, March 1999, p. 1432-1438, Vol. 67, No. 3
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Rosenberger, C. M., Scott, M. G., Gold, M. R., Hancock, R. E. W., Finlay, B. B.
(2000). Salmonella typhimurium Infection and Lipopolysaccharide Stimulation Induce Similar Changes in Macrophage Gene Expression. J. Immunol.
164: 5894-5904
[Abstract]
[Full Text]